Two notable examples are the use of PARP inhibitors in BRCA1/2‐mutated cancers and immune checkpoint inhibitors in tumors with mismatch repair deficiency [55, 56]. This evidence concerns the gene PARP1 and mismatch repair cancer syndrome 1.